MCID: RFR004
MIFTS: 29

Refractory Hematologic Cancer

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Refractory Hematologic Cancer

MalaCards integrated aliases for Refractory Hematologic Cancer:

Name: Refractory Hematologic Cancer 12 15
Refractory Hematologic Malignancy 73

Classifications:



External Ids:

Disease Ontology 12 DOID:712
NCIt 50 C27357
UMLS 73 C1335724

Summaries for Refractory Hematologic Cancer

Disease Ontology : 12 A hematologic cancer that is located in the blood or bone marrow that doesn't respond to treatment.

MalaCards based summary : Refractory Hematologic Cancer, also known as refractory hematologic malignancy, is related to refractory hairy cell leukemia and leukocyte disease. An important gene associated with Refractory Hematologic Cancer is CD22 (CD22 Molecule), and among its related pathways/superpathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Post-translational modification- synthesis of GPI-anchored proteins. The drugs Everolimus and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and liver.

Related Diseases for Refractory Hematologic Cancer

Diseases related to Refractory Hematologic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 refractory hairy cell leukemia 30.4 CD22 CD52 CDA CSF3 MAP2K7 MSLN
2 leukocyte disease 9.8 CD22 CSF3
3 pancreas adenocarcinoma 9.8 MAP2K7 MSLN
4 hematologic cancer 9.7 CD22 CDA CSF3
5 lymphoma, non-hodgkin, familial 9.7 CD22 CD52 CSF3
6 leukemia, acute myeloid 9.6 CD22 CSF3 MAP2K7

Graphical network of the top 20 diseases related to Refractory Hematologic Cancer:



Diseases related to Refractory Hematologic Cancer

Symptoms & Phenotypes for Refractory Hematologic Cancer

Drugs & Therapeutics for Refractory Hematologic Cancer

Drugs for Refractory Hematologic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
2
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
3
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Not Applicable 22916-47-8 4189
4
Hydrocortisone acetate Approved, Vet_approved Phase 2,Phase 1 50-03-3
5
leucovorin Approved Phase 2,Phase 1 58-05-9 6006 143
6
Cytarabine Approved, Investigational Phase 2,Phase 1 147-94-4 6253
7
Methotrexate Approved Phase 2,Phase 1 59-05-2, 1959-05-2 126941
8
Hydrocortisone Approved, Vet_approved Phase 2,Phase 1 50-23-7 5754
9
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
10
Doxorubicin Approved, Investigational Phase 1, Phase 2,Phase 2 23214-92-8 31703
11
Idelalisib Approved Phase 2,Phase 1 870281-82-6
12
Fludarabine Approved Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
13
Thiotepa Approved, Investigational Phase 2,Phase 1 52-24-4 5453
14
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
15
Melphalan Approved Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
16
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
17
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
18
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
19
Busulfan Approved, Investigational Phase 1, Phase 2,Not Applicable 55-98-1 2478
20
Mycophenolic acid Approved Phase 1, Phase 2,Phase 2,Not Applicable 24280-93-1 446541
21
Vidarabine Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable 24356-66-9 32326 21704
22
alemtuzumab Approved, Investigational Phase 1, Phase 2 216503-57-0
23
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
24
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
25
Mesna Approved, Investigational Phase 2,Phase 1 3375-50-6 598
26
Aldesleukin Approved Phase 2,Phase 1 85898-30-2, 110942-02-4
27
Nivolumab Approved Phase 1, Phase 2,Phase 2 946414-94-4
28
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
29
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
30
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
31
Lomustine Approved, Investigational Phase 1, Phase 2 13010-47-4 3950
32
Daratumumab Approved Phase 1, Phase 2 945721-28-8
33 Pomalidomide Approved Phase 1, Phase 2 19171-19-8
34
Lenograstim Approved, Investigational Phase 2,Not Applicable 135968-09-1
35
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
36
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
37
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
38
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
39
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
41
Doxil Approved June 1999 Phase 1, Phase 2,Phase 2 31703
42
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
43 Anti-Bacterial Agents Phase 2,Phase 1,Not Applicable
44 Antibiotics, Antitubercular Phase 2,Phase 1,Not Applicable
45 Immunologic Factors Phase 2,Phase 1,Not Applicable
46 Immunosuppressive Agents Phase 2,Phase 1,Not Applicable
47 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
48 Antifungal Agents Phase 2,Phase 1,Not Applicable
49 Antimetabolites Phase 2,Phase 1,Not Applicable
50 Hydrocortisone-17-butyrate Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) Completed NCT00086125 Phase 2 ridaforolimus
2 506U78 in Treating Patients With Refractory Hematologic Cancer Completed NCT00002970 Phase 2 nelarabine;methotrexate;cytarabine;therapeutic hydrocortisone
3 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
4 Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies Completed NCT01796470 Phase 2 Entospletinib;Idelalisib
5 Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies Completed NCT00143559 Phase 2 Systematic chemotherapy and antibodies
6 Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma Completed NCT00047021 Phase 2 cytarabine;mitoxantrone hydrochloride
7 Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies Completed NCT00202917 Phase 1, Phase 2 Fludarabine;Thiotepa;Melphalan;OKT-3
8 Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma Completed NCT00004907 Phase 1, Phase 2 busulfan;cyclophosphamide;etoposide
9 Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00085449 Phase 1, Phase 2 cyclosporine;fludarabine phosphate;melphalan;mycophenolate mofetil
10 Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies Recruiting NCT02061761 Phase 1, Phase 2
11 9-ING-41 in Patients With Advanced Cancers Recruiting NCT03678883 Phase 1, Phase 2 9-ING-41;Gemcitabine - 21 day cycle;Doxorubicin.;Lomustine;Carboplatin.;Nab paclitaxel.;Paclitaxel.;Gemcitabine - 28 day cycle
12 An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma Recruiting NCT01592370 Phase 1, Phase 2 Pomalidomide;Dexamethasone
13 IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT Recruiting NCT03696537 Phase 1, Phase 2 Fludarabine
14 Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy Recruiting NCT02903810 Phase 1, Phase 2
15 Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Active, not recruiting NCT01799889 Phase 2 Entospletinib;Entospletinib SDD
16 Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Not yet recruiting NCT03739606 Phase 2
17 A Study of BMS-863233 in Patients With Hematologic Cancer Terminated NCT00838890 Phase 1, Phase 2 Cdc7-inhibitor (BMS-863233);Cdc7-inhibitor (BMS-863233)
18 Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers. Terminated NCT00354172 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;methylprednisolone;mycophenolate mofetil
19 Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation Terminated NCT02259348 Phase 2 Cyclophosphamide;Fludarabine;Melphalan;Thiotepa;Rituximab
20 Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients Terminated NCT02433483 Phase 2 Cytarabine;Intrathecal Triples
21 Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Withdrawn NCT02718755 Phase 2 Fludarabine;Cytarabine;Erwinase
22 Therapy for Progressive and/or Refractory Hematologic Malignancies Withdrawn NCT02223312 Phase 1, Phase 2
23 XK469R in Treating Patients With Refractory Hematologic Cancer Completed NCT00095797 Phase 1 R(+)XK469
24 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT01658319 Phase 1 fludarabine phosphate;methoxyamine
25 Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer Completed NCT00900614 Phase 1 APR-246
26 Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies Completed NCT00718757 Phase 1 Dexamethasone;Irinotecan;Vincristine
27 Study of ABT-751 in Patients With Refractory Hematologic Malignancies Completed NCT00047489 Phase 1 ABT-751
28 Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies Completed NCT00824135 Phase 1 Clofarabine;Thiotepa;Melphalan;Mycophenolate mofetil;Rituximab
29 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy Completed NCT00990587 Phase 1 Ciclopirox Olamine
30 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Completed NCT00161187 Phase 1
31 A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Completed NCT01321346 Phase 1 Panobinostat;Cytarabine;Panobinostat
32 Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies Completed NCT02160951 Phase 1 LGH447
33 A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies Completed NCT00506402 Phase 1 MKC-1
34 Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT01900509 Phase 1 Bendamustine;Clofarabine;Etoposide;Etoposide phosphate;Dexamethasone
35 Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies Completed NCT00710528 Phase 1 CAL-101
36 An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate Completed NCT01844869 Phase 1 omacetaxine mepesuccinate
37 Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer Completed NCT02240719 Phase 1 everolimus;bendamustine hydrochloride
38 Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies Completed NCT00660920 Phase 1 Ponatinib
39 Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies Completed NCT00908167 Phase 1 Sorafenib;Cytarabine;Clofarabine
40 Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies Completed NCT00697671 Phase 1 Interleukin-2 (IL-2);Clofarabine;Cyclophosphamide;Etoposide
41 Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Completed NCT02017613 Phase 1 RP6530
42 Phase I Study of OPB-51602 in Patients With Hematologic Malignancies Completed NCT01344876 Phase 1 OPB-51602
43 3-AP and Cytarabine in Treating Patients With Hematologic Cancer Completed NCT00064090 Phase 1 cytarabine;triapine
44 A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation Completed NCT01068301 Phase 1 Plerixafor
45 Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed NCT02212561 Phase 1 Selinexor;Fludarabine;Cytarabine;methotrexate/hydrocortisone/cytarabine
46 Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies Completed NCT01871675 Phase 1 IPI-145;Rituximab;Bendamustine
47 Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors Completed NCT00640796 Phase 1 Chemotherapy
48 A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma Completed NCT01209130 Phase 1 DCDT2980S;rituximab
49 A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma Completed NCT01290549 Phase 1 Polatuzumab Vedotin;Rituximab
50 Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies Completed NCT02270788 Phase 1 Crenolanib;Sorafenib;methotrexate, hydrocortisone and cytarabine with leucovorin

Search NIH Clinical Center for Refractory Hematologic Cancer

Genetic Tests for Refractory Hematologic Cancer

Anatomical Context for Refractory Hematologic Cancer

MalaCards organs/tissues related to Refractory Hematologic Cancer:

41
Bone, Bone Marrow, Liver, T Cells, Myeloid, Nk Cells, Pancreas

Publications for Refractory Hematologic Cancer

Articles related to Refractory Hematologic Cancer:

# Title Authors Year
1
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. ( 27269947 )
2016
2
Low dose total body irradiation followed by allogeneic lymphocyte infusion for refractory hematologic malignancy--an updated review. ( 15291347 )
2004
3
Dose-escalated total body irradiation and autologous stem cell transplantation for refractory hematologic malignancy. ( 12007954 )
2002
4
Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. ( 12091334 )
2002

Variations for Refractory Hematologic Cancer

Expression for Refractory Hematologic Cancer

Search GEO for disease gene expression data for Refractory Hematologic Cancer.

Pathways for Refractory Hematologic Cancer

Pathways related to Refractory Hematologic Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.22 CD22 CSF3
2
Show member pathways
10.95 CD52 MSLN
3 10.61 CD22 CSF3

GO Terms for Refractory Hematologic Cancer

Cellular components related to Refractory Hematologic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.26 CD52 CDA CSF3 MSLN
2 anchored component of membrane GO:0031225 8.62 CD52 MSLN

Molecular functions related to Refractory Hematologic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.62 CD22 MAP2K7

Sources for Refractory Hematologic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....